N@N

Market Maker Surveillance Report. RNN, OCCF, CWST, NVGN, CLDA, DSCI, Winning Stocks With Lowest Price Friction For Monday, Jan

_{//stocks-investing.news-articles.net/content/201 .. s-with-lowest-price-friction-for-monday-jan.html}
^{Published in Stocks and Investing on Monday, January 24th 2011 at 17:50 GMT by WOPRAI}  

January 24, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 2640 companies with "abnormal" market making, 3242 companies with positive Friction Factors and 1991 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. REXAHN PHARMACEUTICALS INC (AMEX:RNN), OPTICAL CABLE CORP (NASDAQ:OCCF), CASELLA WASTE SYSTEMS INC-A (NASDAQ:CWST), NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN), CLINICAL DATA INC (NASDAQ:CLDA), DERMA SCIENCES INC (NASDAQ:DSCI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     RNN        $0.270       20.77%       4,754,535       56.04%       3,406,108       40.15%       1,348,427       49,942  
     OCCF       $1.350       36.49%       351,116         50.64%       336,950         48.60%       14,166          105     
     CWST       $1.300       20.77%       416,485         58.33%       291,472         40.82%       125,013         962     
     NVGN       $0.370       33.22%       1,184,308       52.56%       1,112,030       49.35%       72,278          1,953   
     CLDA       $10.220      68.00%       7,765,636       49.81%       7,162,693       45.95%       602,943         590     
     DSCI       $1.350       25.57%       162,417         52.69%       125,502         40.71%       36,915          273     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows DSCI with a dollar gain Monday of $1.35000 and a Friction Factor of 273 shares. That means that it only took 273 more shares of buying than selling to move DSCI higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

REXAHN PHARMACEUTICALS INC (AMEX:RNN) - Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its drug candidates in Phase II clinical trials include Archexin, the lead anticancer drug candidate is an inhibitor of the protein kinase Akt for the treatment of pancreatic cancer and renal cell carcinoma; Serdaxin for the treatment of depression and neurodegenerative disorders; and Zoraxel, a drug for sexual dysfunction that modulates the sexual activity control center in the brain. Its pre-clinical pipeline products include RX-1792, a molecule targeted anticancer drug candidate; RX-5902, a molecule microtubule inhibitor anticancer drug candidate; RX-3117, a molecule anti-metabolite nucleoside anticancer drug candidate; RX-8243, a molecule aurora kinase inhibitor anticancer drug candidate; RX-0201-Nano, nanoliposomal anticancer Akt-1 inhibitor; RX-0047-Nano, nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101 & RX-21202, a nano-polymer anticancer. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; and Revaax Pharmaceuticals LLC. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

OPTICAL CABLE CORP (NASDAQ:OCCF) - Optical Cable Corporation provides fiber optic and copper data communications cabling and connectivity solutions primarily for the enterprise market in the United States and internationally. It designs, manufactures, markets, and sells fiber optic cable products that include A-series assembly fiber optic cables for jumpers and pigtails; B-series breakout fiber optic cables for in campus and industrial complex installations; D-Series fiber optic cables for longer distance, buried, and over head applications; and G-series subgrouping fiber optic cables. The company also markets and sells copper datacom cable products, including unshielded twisted pair and shielded twisted pair. In addition, Optical Cable Corporation designs, manufactures, markets, and sells fiber optic enterprise connectivity products that provide a range of fiber distribution solutions for the equipment room, telecommunication closet, datacenter, and workstation; copper enterprise connectivity products, which offer customers a line of copper connectivity components necessary for the equipment room, telecommunications closet, datacenter, and workstation; rack solutions that provide an array of network, data storage, and telecommunications management systems for commercial and residential uses; and residential systems, which offer wiring products designed for single dwelling and multiple dwelling residential uses. Further, it designs, manufactures, markets, and sells applied interconnect systems, including specialty fiber optic connectors and connectivity components, ruggedized copper datacom connectors, and related systems and solutions for the military and harsh environment applications. Its products also have applications in industrial, mining, and broadcast applications. The company sells its products to various distributors, original equipment manufacturers, resellers, and end-users. Optical Cable Corporation was founded in 1983 and is headquartered in Roanoke, Virginia.

CASELLA WASTE SYSTEMS INC-A (NASDAQ:CWST) - Casella Waste Systems, Inc. provides solid waste management services consisting of collection, transfer, disposal, and recycling services primarily in the eastern United States. It offers non-hazardous solid waste services, including collection operations, transfer stations, material recycling facilities, and disposal facilities. The company also markets recyclable metals, aluminum, plastics, and paper and corrugated cardboard, which have been processed at its facilities; and recyclables purchased from third parties. In addition, it generates and sells electricity under a contract at a waste-to-energy facility. The company serves residential, commercial, municipal, and industrial customers in Vermont, New Hampshire, New York, Massachusetts, Maine, Connecticut, Pennsylvania, New Jersey, North Carolina, Tennessee, Georgia, Florida, Michigan, and Wisconsin. It has a 50% joint venture with US GreenFiber LLC to manufacture, market, and sell cellulose insulation made from recycled fiber. As of May 31, 2009, the company owned and/or operated 32 solid waste collection operations, 31 transfer stations, 37 recycling facilities, 9 subtitle D landfills, 1 landfill permitted to accept construction and demolition materials, and 1 waste-to-energy facility. Casella Waste Systems, Inc. was founded in 1975 and is headquartered in Rutland, Vermont.

NOVOGEN LIMITED-SPONS ADR (NASDAQ:NVGN) - Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The companys consumer healthcare products comprise Promensil, a range of natural products specifically for womens health; Vinalac, a probiotic formula to help prevent childhood allergies, such as eczema in children at risk of an allergy; Aliten for weight control; and Trinovin, for the enhancement and maintenance of mens health. It focuses on oncology, cardiovascular, dermatological, and anti-inflammatory programs. The companys programs include Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and prostate, and cervical cancers; Triphendiol, a phase I signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma; NV-128, a pre-clinical stage cancer compound to promote cancer cell death in multidrug resistant ovarian cancer cells by targeting the AKT-mTOR pathway; and GLYC-101, a phase II product for the treatment of wounds following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers. Novogens programs also include NV-143, a derivative of triphendiol and a pan acting ant-cancer; NV-04, a program for cardiovascular disease; NV-27, an oral agent to prevent arterial restenosis following coronary artery angioplasty; and NV-07 for the protection of mice against UV-induced inflammatory changes in the skin and against UV-induced skin immune suppression. In addition, it develops NV-52 for the treatment of inflammatory bowel disease; and FAIMs, flavonoid anti-inflammatory molecules to avoid cardiovascular, gastrointestinal, and renal side effects associated with anti-inflammatory drugs. Novogen Limited offers its products in Australia, North America, and Europe. The company was founded in 1994 and is headquartered in North Ryde, Australia.

CLINICAL DATA INC (NASDAQ:CLDA) - Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers. The company was founded in 1969 and is headquartered in Newton, Massachusetts.

DERMA SCIENCES INC (NASDAQ:DSCI) - Derma Sciences, Inc. engages in manufacturing, marketing, and selling wound care, wound closure and specialty securement devices, and skin care products. The company offers advanced/active wound care products comprising Medihoney dressings to manage non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings for prophylactic use to prevent hospital or community acquired infections through wound sites; Algicell Ag, an antimicrobial dressing; Xtrasorb dressings that convert fluid within the dressing to a gel and locks the exudates into the dressing; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also provides traditional wound care products, such as gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as adhesive bandages and related first aid products for the medical, industrial, private label, and retail markets. In addition, the company offers wound closure strips, nasal tube fasteners, and catheter fasteners to doctors, clinics, nursing homes, hospitals, and other institutions; and barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to nursing homes, hospitals, and home healthcare agencies. Further, it involves in developing DSC127, an angiotensin analog for use in wound healing and scar reduction. The company serves wound care centers, long-term care facilities, hospitals, home healthcare agencies, physicians offices, and closed door pharmacies. It sells its products primarily through independent distributors in the United States, Canada, and internationally. The company was founded in 1984 and is headquartered in Princeton, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net